SO SOLV Solventum Загрузка... : Бычьи и медвежьи мнения аналитиков

Management raised full-year guidance for sales, operating margin, and EPS, reflecting strong execution, the benefit of a tariff refund, and confidence in continued momentum; they reiterate an earlier-than-expected achievement of long-range plan targets.

Goldman Sachs upgrades CIB to Buy, KeyBanc upgrades FLY to Overweight.

3M's reported results include a gain from changes in the value of its remaining stake in Solventum, but no operational information about Solventum itself.

Solventum is trading at a 7-8 PE (vs peers at 25+ PE) after paying down high-interest debt and authorizing a $1B buyback supported by ~$1B in normalized FCF. The stock price is temporarily depressed due to "index churn" and forced selling by 3M's dividend investors, creating a mispricing before healthcare funds step in and one-time spinoff costs fade. Go long on SOLV as an undervalued, relatively safe turnaround play with growth potential in AI medical billing. ERP migration issues causing supply chain disruptions, tariff impacts, and strict 2027 rebranding deadlines.

Management is confident in its momentum, expecting organic growth to accelerate towards its 4-5% long-term target, while expanding margins despite tariff headwinds. The tone is optimistic about meeting or exceeding its long-range plan goals by 2028.

Thermo Fisher acquired Solventum's filtration and separation business to extend bioproduction capabilities; Solventum divests a non-core unit for cash.

Winding down transition services agreements with Solventum will reduce 3M's corporate income by $50-75 million in 2026, indicating a decreasing dependency but also a potential headwind for 3M's other income.

Thermo Fisher adds bioprocessing and industrial filtration capabilities, expanding its addressable market and customer base.